Securities Registration: Employee Benefit Plan (s-8)
30 Mars 2022 - 1:22PM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on March 29, 2022
Registration No. 333-
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The
Securities Act of 1933
CHECKMATE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
37-1657129 |
(State or other jurisdiction of
incorporation or organization) |
|
(I.R.S. Employer
Identification No.) |
245 Main Street, 2nd Floor
Cambridge, MA 02142
(617) 682-3625
(Address, including zip code and telephone number, including area code, of Registrants principal executive offices)
Checkmate Pharmaceuticals, Inc. 2020 Stock Option and Incentive Plan
(Full title of the plans)
Robert Dolski
Chief
Financial Officer
245 Main Street, 2nd Floor
Cambridge, MA 02142
(617) 682-3625
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Mitchell Bloom, Esq.
Benjamin Marsh, Esq.
Goodwin Procter LLP
100
Northern Avenue
Boston, MA 02210
(617) 570-1000
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated
filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E
This Registration Statement has been filed by Checkmate Pharmaceuticals, Inc. to register 865,223 additional shares of common stock, par value
$0.0001 per share (Common Stock) available for issuance under the Checkmate Pharmaceuticals, Inc. 2020 Stock Option and Incentive Plan (the 2020 Plan). This Registration Statement relates to securities of the same class as
those that were previously registered by the registrant on a Registration Statement on Form S-8
filed with the Securities and Exchange Commission on August 11, 2020 (File. No. 333-244375)
(the 2020 Registration Statement).
Pursuant to General Instruction E to
Form S-8 regarding registration of additional securities, the entire contents of the 2020 Registration Statement are incorporated herein by reference, except to the extent supplemented, amended or
superseded by the information set forth herein.
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
Refer to the
Exhibit Index for a list of exhibits filed as part of this registration statement, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, State of
Massachusetts, on this 29th day of March 2022.
|
|
|
CHECKMATE PHARMACEUTICALS, INC. |
|
|
By: |
|
/s/ Robert Dolski |
|
|
Name: Robert Dolski |
|
|
Title: Chief Financial Officer |
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Alan Bash and Robert Dolski, as such
persons true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such persons name, place and stead,
in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in
connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and
every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the
date indicated.
|
|
|
|
|
Name |
|
Title |
|
Date |
|
|
|
/s/ Alan Bash |
|
Chief Executive Officer and Director |
|
March 25, 2022 |
Alan Bash |
|
(Principal Executive Officer) |
|
|
|
|
|
/s/ Robert Dolski |
|
Chief Financial Officer |
|
March 25, 2022 |
Robert Dolski |
|
(Principal Financial and Accounting Officer) |
|
|
|
|
|
/s/ Michael Powell |
|
Director (Chairman) |
|
March 25, 2022 |
Michael Powell, Ph.D. |
|
|
|
|
|
|
|
/s/ Alan Fuhrman |
|
Director |
|
March 25, 2022 |
Alan Fuhrman |
|
|
|
|
|
|
|
/s/ Peter Colabuono |
|
Director |
|
March 25, 2022 |
Peter Colabuono |
|
|
|
|
|
|
|
/s/ Keith Flaherty |
|
Director |
|
March 25, 2022 |
Keith Flaherty, M.D. |
|
|
|
|
|
|
|
/s/ Oren Isacoff |
|
Director |
|
March 25, 2022 |
Oren Isacoff, M.D. |
|
|
|
|
|
|
|
/s/ Jon Wigginton |
|
Director |
|
March 25, 2022 |
Jon Wigginton |
|
|
|
|
|
|
|
/s/ Joy Yan |
|
Director |
|
March 25, 2022 |
Joy Yan |
|
|
|
|
Checkmate Pharmaceuticals (NASDAQ:CMPI)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Checkmate Pharmaceuticals (NASDAQ:CMPI)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Checkmate Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur Checkmate Pharmaceuticals, Inc.